Role of Dicer As a Prognostic Predictor for Survival in Cancer Patients: a Systematic Review with a Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Sep 30

PMID 27682871

Citations 9

Authors

Wanying Shan

Chaoyang Sun

Bo Zhou

Ensong Guo

Hao Lu

Meng Xia

Kezhen Li

Danhui Weng

Xingguang Lin

Li Meng

Ding Ma

Gang Chen

Affiliations

Soon will be listed here.

Abstract

Objective: The role of Dicer in the prognosis of cancer patients remains controversial. This systematic review is attempted to assess the influence of Dicer as a prognostic predictor for survival in diverse types of cancers.

Methods: Studies were selected as candidates if they published an independent evaluation of Dicer expression level together with the correlation with prognosis in cancers. Random-effect model was applied in this meta-analysis. Heterogeneity between studies was assessed by Q-statistic with P < 0.10 to be statistically significant. Publication bias was investigated using funnel plot and test with Begg's and Egger's test. P < 0.05 was regarded as statistically significant.

Results: 24 of 44 articles revealed low Dicer status as a predictor of poor prognosis. The aggregate result of overall survival (OS) indicated that low Dicer expression level resulted in poor clinical outcomes, and subgroup of IHC and RT-PCR method both revealed the same result. Overall analysis of progression-free survival (PFS) showed the same result as OS, and both the two subgroups divided by laboratory method revealed positive results. Subgroup analysis by tumor types showed low dicer levels were associated with poor prognosis in ovarian cancer (HR = 1.93, 95% CI: 1.19-3.15), otorhinolaryngological tumors (HR = 2.39, 95% CI: 1.70-3.36), hematological malignancies (HR = 2.45, 95% CI: 1.69-3.56) and neuroblastoma (HR = 4.03, 95% CI: 1.91-8.50).

Conclusion: Low Dicer status was associated with poor prognosis in ovarian cancer, otorhinolaryngological tumors and ematological malignancies. More homogeneous studies with high quality are needed to further confirm our conclusion and make Dicer a useful parameter in clinical application.

Citing Articles

The role of miR-200 family in the regulation of hallmarks of cancer.

Klicka K, Grzywa T, Mielniczuk A, Klinke A, Wlodarski P Front Oncol. 2022; 12:965231.

PMID: 36158660 PMC: 9492973. DOI: 10.3389/fonc.2022.965231.

APE1 controls DICER1 expression in NSCLC through miR-33a and miR-130b.

Antoniali G, Dalla E, Mangiapane G, Zhao X, Jing X, Cheng Y Cell Mol Life Sci. 2022; 79(8):446.

PMID: 35876890 PMC: 9314295. DOI: 10.1007/s00018-022-04443-7.

MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis.

Fodor A, Lazar A, Buchman C, Tiperciuc B, Orasan O, Cozma A Int J Mol Sci. 2021; 22(12).

PMID: 34199293 PMC: 8231835. DOI: 10.3390/ijms22126337.

Dietary Lutein Plus Zeaxanthin Intake and DICER1 rs3742330 A > G Polymorphism Relative to Colorectal Cancer Risk.

Kim J, Lee J, Oh J, Chang H, Sohn D, Kwon O Sci Rep. 2019; 9(1):3406.

PMID: 30833603 PMC: 6399314. DOI: 10.1038/s41598-019-39747-5.

Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells.

DAlmeida O, Mothar O, Apraku Bondzie E, Lieumo Y, Tagne L, Gupta S BMC Cancer. 2019; 19(1):136.

PMID: 30744585 PMC: 6371494. DOI: 10.1186/s12885-019-5337-6.

References

Zhao H, Zhang L, Guo S, Yuan T, Xia B, Qu F . Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab. Med Oncol. 2014; 31(10):206. DOI: 10.1007/s12032-014-0206-2. View

Valencak J, Schmid K, Trautinger F, Wallnofer W, Muellauer L, Soleiman A . High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas. J Dermatol Sci. 2011; 64(3):185-90. DOI: 10.1016/j.jdermsci.2011.08.011. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Bahubeshi A, Tischkowitz M, Foulkes W . miRNA processing and human cancer: DICER1 cuts the mustard. Sci Transl Med. 2011; 3(111):111ps46. DOI: 10.1126/scitranslmed.3002493. View

He L, Wang H, Zhang L, Huang L, Li J, Xiong Y . Prognostic significance of low DICER expression regulated by miR-130a in cervical cancer. Cell Death Dis. 2014; 5:e1205. PMC: 4047899. DOI: 10.1038/cddis.2014.127. View

Merritt W, Lin Y, Han L, Kamat A, Spannuth W, Schmandt R . Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008; 359(25):2641-50. PMC: 2710981. DOI: 10.1056/NEJMoa0803785. View

Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, Benz C . Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2006; 282(2):1479-86. DOI: 10.1074/jbc.M609383200. View

Sahasrabuddhe N, Huang T, Kumar P, Yang Y, Ghosh B, Leach S . Ablation of Dicer leads to widespread perturbation of signaling pathways. Biochem Biophys Res Commun. 2015; 463(3):389-94. PMC: 4696065. DOI: 10.1016/j.bbrc.2015.05.077. View

Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K . Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005; 96(2):111-5. PMC: 11158408. DOI: 10.1111/j.1349-7006.2005.00015.x. View

10.

Lin R, Lin Y, Chen J, Kuo H, Chen Y, Diccianni M . microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010; 70(20):7841-50. PMC: 4095771. DOI: 10.1158/0008-5472.CAN-10-0970. View

11.

Diaz-Garcia C, Agudo-Lopez A, Perez C, Lopez-Martin J, Rodriguez-Peralto J, de Castro J . DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis. 2013; 34(5):1031-8. DOI: 10.1093/carcin/bgt022. View

12.

Guo X, Liao Q, Chen P, Li X, Xiong W, Ma J . The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2011; 138(1):49-56. DOI: 10.1007/s00432-011-1058-1. View

13.

Sarasquete M, Gutierrez N, Misiewicz-Krzeminska I, Paiva B, Chillon M, Alcoceba M . Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica. 2010; 96(3):468-71. PMC: 3046281. DOI: 10.3324/haematol.2010.033845. View

14.

Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, DellAquila E . Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. Eur J Cancer. 2012; 49(6):1501-8. DOI: 10.1016/j.ejca.2012.11.014. View

15.

Weiss G, Bemis L, Nakajima E, Sugita M, Birks D, Robinson W . EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008; 19(6):1053-9. DOI: 10.1093/annonc/mdn006. View

16.

Zhang B, Chen H, Zhang L, Dakhova O, Zhang Y, Lewis M . A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene. 2013; 33(24):3099-108. PMC: 3916938. DOI: 10.1038/onc.2013.281. View

17.

Stratmann J, Wang C, Gnosa S, Wallin A, Hinselwood D, Sun X . Dicer and miRNA in relation to clinicopathological variables in colorectal cancer patients. BMC Cancer. 2011; 11:345. PMC: 3199872. DOI: 10.1186/1471-2407-11-345. View

18.

Lu J, Getz G, Miska E, Alvarez-Saavedra E, Lamb J, Peck D . MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043):834-8. DOI: 10.1038/nature03702. View

19.

Nelson K, Weiss G . MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008; 7(12):3655-60. DOI: 10.1158/1535-7163.MCT-08-0586. View

20.

Martin M, Payton J, Link D . Dicer and outcomes in patients with acute myeloid leukemia (AML). Leuk Res. 2009; 33(8):e127. DOI: 10.1016/j.leukres.2009.02.003. View